Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Lasmiditan in Healthy Chinese Subjects
NCT04081324Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lasmiditan in migraine (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity AUC(0-∞) at 24 hours, Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) at Day 10 and 2 more. Started Nov 2019; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04081324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081324.